On November 5, 2024, PrognomiQ, a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, announced the succesful completion of a $34 million Series D financing. The round was led by Seer with participation from Catalio Capital Management, aMoon, Invus, and Bruker. Wilson Sonsini Goodrich & Rosati advised PrognomiQ on patent matters related to the transaction.

PrognomiQ will use the additional capital to advance development of an early detection test for lung cancer, which the company plans to provide as a lab developed test and later as an In Vitro Diagnostics (IVD) test. The company is also actively enlisting participants for a comprehensive lung cancer study involving 15,000 subjects which was launched in 2023, aiming to aid the registration of the IVD product.

The Wilson Sonsini team that advised PrognomiQ on patent matters related to the transaction includes Bill Barrett, Vern Norviel, Rona Lamiquiz, Laci Adolfo, and Steven Gore.

For more information, please see PrognomiQ's news release. Additional coverage can be found on Endpoints News.